NCT06413433Phase 3Recruiting

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

Study sponsor: Axsome Therapeutics, Inc. · AXSM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-12Estimated
Enrollment · participants450Estimated
Source updated2026-07-28Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Dec 2025. After: Dec 2026.

Check registry source